AbbVie Inc (ABBV)vsDocGo Inc (DCGO)
ABBV
AbbVie Inc
$248.67
-0.53%
HEALTHCARE · Cap: $430.82B
DCGO
DocGo Inc
$0.67
+15.31%
HEALTHCARE · Cap: $61.74M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 21240% more annual revenue ($64.39B vs $301.71M). ABBV leads profitability with a 9.8% profit margin vs -62.2%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
DCGO
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-64.0%
Fair Value
$151.19
Current Price
$248.67
$97.48 premium
Margin of Safety
+65.4%
Fair Value
$2.10
Current Price
$0.67
$1.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -141.9% — below average capital efficiency
Revenue declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : DCGO
The strongest argument for DCGO centers on Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : DCGO
The primary concerns for DCGO are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while DCGO is a turnaround play — different risk/reward profiles.
DCGO carries more volatility with a beta of 0.99 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 36/100) and 10.2% revenue growth. DCGO offers better value entry with a 65.4% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
DocGo Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DocGo Inc. is a leading mobile healthcare service provider focused on enhancing patient accessibility and optimizing healthcare delivery through its cutting-edge logistics and telehealth solutions. The company specializes in urgent care, diagnostic testing, and health screenings, effectively addressing key healthcare challenges across diverse environments and significantly improving patient experiences. With a strong commitment to innovation and expanding access to healthcare, DocGo is well-positioned in the dynamic healthtech sector, making it an attractive investment opportunity for institutional investors interested in sustainable growth and impactful social contributions.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?